Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04896385 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT04896385 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 60 participants.
The verdict
NCT04896385, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the Mechanism Of Action (MOA) of ruxolitinib cream in vitiligo by assessing the change in biomarkers.
Interventions
- DRUG Vehicle Cream
- DRUG Ruxolitinib cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-06-23 |
| Est. Completion | 2023-07-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04896385
The ClinicalTrials.gov registry entry for NCT04896385 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Cream is the first listed.
NCT04896385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04896385 about?
NCT04896385 is a clinical study titled "A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)". The purpose of the study is to evaluate the Mechanism Of Action (MOA) of ruxolitinib cream in vitiligo by assessing the change in biomarkers.
What is the current status of trial NCT04896385?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2021-06-23. Estimated completion is 2023-07-10.
What interventions are being tested in trial NCT04896385?
The interventions under investigation include: Vehicle Cream (DRUG), Ruxolitinib cream (DRUG).
Who is sponsoring clinical trial NCT04896385?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.